WilmerHale Reps Cydan in Raising $34M to Accelerate New Treatments for Rare Genetic Diseases

WilmerHale Reps Cydan in Raising $34M to Accelerate New Treatments for Rare Genetic Diseases

Firm News

Cydan, the first orphan drug accelerator dedicated to advancing therapies that improve the lives of patients with rare genetic diseases, announced a new round of financing, raising a committed total of $34 million to advance the company's efforts to create new and innovative therapies for patients living with rare genetic diseases. The proceeds from this round of financing will fund Cydan II, Inc., continuing the mission of Cydan Development, Inc.

The WilmerHale team representing Cydan included Gary Schall, Stephanie Singer and Bill Caporizzo.

Read Cydan's press release for more information.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.